BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 25259809)

  • 1. Options for treating carbapenem-resistant Enterobacteriaceae.
    Rafailidis PI; Falagas ME
    Curr Opin Infect Dis; 2014 Dec; 27(6):479-83. PubMed ID: 25259809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of multidrug-resistant Enterobacteriaceae.
    Bassetti M; Peghin M; Pecori D
    Curr Opin Infect Dis; 2016 Dec; 29(6):583-594. PubMed ID: 27584587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination.
    Demiraslan H; Dinc G; Ahmed SS; Elmali F; Metan G; Alp E; Doganay M
    J Chemother; 2014 Oct; 26(5):276-81. PubMed ID: 24070112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
    Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
    Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
    Evren E; Azap OK; Çolakoğlu Ş; Arslan H
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.
    Tängdén T; Giske CG
    J Intern Med; 2015 May; 277(5):501-12. PubMed ID: 25556628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
    Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
    Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.
    Betts JW; Phee LM; Hornsey M; Woodford N; Wareham DW
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3541-6. PubMed ID: 24687491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group.
    Levy Hara G; Gould I; Endimiani A; Pardo PR; Daikos G; Hsueh PR; Mehtar S; Petrikkos G; Casellas JM; Daciuk L; Paciel D; Novelli A; Saginur R; Pryluka D; Medina J; Savio E
    J Chemother; 2013 Jun; 25(3):129-40. PubMed ID: 23783137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates.
    Stein C; Makarewicz O; Bohnert JA; Pfeifer Y; Kesselmeier M; Hagel S; Pletz MW
    PLoS One; 2015; 10(6):e0126479. PubMed ID: 26067824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular surveillance and clinical outcomes of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae infections.
    Huang SR; Liu MF; Lin CF; Shi ZY
    J Microbiol Immunol Infect; 2014 Jun; 47(3):187-96. PubMed ID: 23200553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant
    Amladi AU; Abirami B; Devi SM; Sudarsanam TD; Kandasamy S; Kekre N; Veeraraghavan B; Sahni RD
    Indian J Med Res; 2019 Feb; 149(2):185-191. PubMed ID: 31219082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
    Shah PG; Shah SR
    J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.